These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 30235716)

  • 21. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
    BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
    d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G
    Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
    Caliman-Fontes AT; Leal GC; Correia-Melo FS; Paixão CS; Carvalho MS; Jesus-Nunes AP; Vieira F; Magnavita G; Bandeira ID; Mello RP; Beanes G; Silva SS; Echegaray M; Carvalho LP; Machado P; Sampaio AS; Cardoso TA; Kapczinski F; Lacerda ALT; Quarantini LC
    Trends Psychiatry Psychother; 2023; 45():e20210298. PubMed ID: 34904800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study.
    Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
    Medicine (Baltimore); 2021 Jul; 100(29):e26769. PubMed ID: 34398056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.
    Mello RP; Echegaray MVF; Jesus-Nunes AP; Leal GC; Magnavita GM; Vieira F; Caliman-Fontes AT; Telles M; Guerreiro-Costa LNF; Souza-Marques B; Bandeira ID; Santos-Lima C; Marback RF; Correia-Melo FS; Lacerda ALT; Quarantini LC
    J Psychiatr Res; 2021 Jun; 138():576-583. PubMed ID: 33991996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
    Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
    Rotroff DM; Corum DG; Motsinger-Reif A; Fiehn O; Bottrel N; Drevets WC; Singh J; Salvadore G; Kaddurah-Daouk R
    Transl Psychiatry; 2016 Sep; 6(9):e894. PubMed ID: 27648916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
    Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
    Nijs M; Wajs E; Aluisio L; Turkoz I; Daly E; Janik A; Borentain S; Singh JB; DiBernardo A; Wiegand F
    Int J Neuropsychopharmacol; 2020 Jul; 23(7):426-433. PubMed ID: 32270176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial.
    Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
    JMIR Res Protoc; 2022 Jan; 11(1):e30163. PubMed ID: 34882570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketamine and Treatment-Resistant Depression.
    Lent JK; Arredondo A; Pugh MA; Austin PN
    AANA J; 2019 Oct; 87(5):411-419. PubMed ID: 31612847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis.
    Zhan Z; Wang X; Chen Q; Xiao Z; Zhang B
    BMJ Open; 2021 Feb; 11(2):e043457. PubMed ID: 33579768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study.
    Araújo-de-Freitas L; Santos-Lima C; Mendonça-Filho E; Vieira F; França RJAF; Magnavita G; Cardoso TL; Correia-Melo FS; Leal GC; Jesus-Nunes AP; Souza-Marques B; Marback R; Teles M; Echegaray MV; Beanes G; Guerreiro-Costa LNF; Mello RP; Rabanea T; Lucchese AC; Abreu N; Lacerda ALT; Quarantini LC
    Psychiatry Res; 2021 Sep; 303():114058. PubMed ID: 34153630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
    Bahji A; Vazquez GH; Zarate CA
    J Affect Disord; 2021 Jan; 278():542-555. PubMed ID: 33022440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ketamine for Depression, 3: Does Chirality Matter?
    Andrade C
    J Clin Psychiatry; 2017 Jun; 78(6):e674-e677. PubMed ID: 28682536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 38. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.
    Mathew SJ; Wilkinson ST; Altinay M; Asghar-Ali A; Chang LC; Collins KA; Dale RM; Hu B; Krishnan K; Kellner CH; Malone DA; Murrough JW; Ostroff RB; Sanacora G; Shao M; Anand A
    Contemp Clin Trials; 2019 Feb; 77():19-26. PubMed ID: 30572160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
    Doty RL; Popova V; Wylie C; Fedgchin M; Daly E; Janik A; Ochs-Ross R; Lane R; Lim P; Cooper K; Melkote R; Jamieson C; Singh J; Drevets WC
    CNS Drugs; 2021 Jul; 35(7):781-794. PubMed ID: 34235612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
    Lipsitz O; Di Vincenzo JD; Rodrigues NB; Cha DS; Lee Y; Greenberg D; Teopiz KM; Ho RC; Cao B; Lin K; Subramaniapillai M; Flint AJ; Kratiuk K; McIntyre RS; Rosenblat JD
    Am J Geriatr Psychiatry; 2021 Sep; 29(9):899-913. PubMed ID: 33478865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.